Clinical Trial Update: 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 PET tracer trial for tauopathy in unclassified parkinsonism (progressive supranuclear palsy and multi-system atrophy) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multi-system Atrophy
• Parkinsonism
• Progressive Supranuclear Palsy

Drugs mentioned

• 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET

Snippet

Sponsor: Fundacion Clinic per a la Recerca Biomédica | Conditions: Progressive Supranuclear Palsy, Multi-System Atrophy | EARLY_Phase 1 | Status: COMPLETED